BRCA2 -associated pancreatic cancer and current screening guidelines

Cancer ◽  
2015 ◽  
Vol 121 (17) ◽  
pp. 3046-3046 ◽  
Author(s):  
Pashtoon Murtaza Kasi ◽  
Katrina S. Pedersen ◽  
Robert R. McWilliams
Keyword(s):  
Pancreatic Cancer ◽  
Screening Guidelines ◽  
Current Screening

scholarly journals Reply to BRCA2 -associated pancreatic cancer and current screening guidelines

Cancer ◽  
2015 ◽  
Vol 121 (17) ◽  
pp. 3047-3047
Author(s):  
Jennifer K. Litton ◽  
Jeffrey H. Lee ◽  
Banu K. Arun
Keyword(s):  
Pancreatic Cancer ◽  
Screening Guidelines ◽  
Current Screening

scholarly journals Screening for pancreatic cancer: a review for general clinicians

2020 ◽  
Vol 58 (3) ◽  
pp. 119-128
Author(s):  
Nathaniel E. Wiest ◽  
Varun P. Moktan ◽  
Sven P. Oman ◽  
Răzvan M. Chirilă
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Screening Tests ◽  
Screening Guidelines ◽  
Incidence And Mortality ◽  
Reduction Strategies ◽  
Risk Patients ◽  
Risk Reduction Strategies ◽  
Current Screening ◽  
Review Current

AbstractPancreatic cancer (PC) is an exceptionally lethal malignancy with increasing incidence and mortality worldwide. One of the principal challenges in the treatment of PC is that the diagnosis is usually made at a late stage when potentially curative surgical resection is no longer an option. General clinicians including internists and family physicians are well positioned to identify high-risk individuals and refer them to centers with expertise in PC screening and treatment where screening modalities can be employed. Here, we provide an up-to-date review of PC precursor lesions, epidemiology, and risk factors to empower the general clinician to recognize high-risk patients and employ risk reduction strategies. We also review current screening guidelines and modalities and preview progress that is being made to improve screening tests and biomarkers.It is our hope that this review article will empower the general clinician to understand which patients need to be screened for PC, strategies that may be used to reduce PC risk, and which screening modalities are available in order to diminish the lethality of PC.

When to Stop Screening: A Review of Breast, Gynecologic, and Colorectal Cancer Screening in Women Over Age 65

2010 ◽  
Vol 11 (1) ◽  
pp. 48-57 ◽  
Author(s):  
Rebecca Bernstein ◽  
Daniel Dejoseph ◽  
Edward M. Buchanan
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Task Force ◽  
The United States ◽  
Screening Tests ◽  
Women Patients ◽  
Cancer Society ◽  
Screening Guidelines ◽  
Health Goals ◽  
Current Screening

Because age alone is not an indicator of health, there is no clear consensus among the various cancer screening guidelines on when to stop cancer screening. For breast, cervical, and colorectal cancer, there are recommended screening tests, while, for other gynecologic cancers, there are not. When discussing with older women patients when to stop cancer screening, we encourage practitioners to review the goals of the screening test, assess the health and functional status of the patient, and discuss her values and health goals. To facilitate this discussion, we review proposed frameworks for determining when to screen older patients for cancer. We also review the concepts of “well” and “frail” older adults. Finally, we review the current screening recommendations for breast, gynecological, and colorectal cancers, and the reasoning behind them, from the United States Preventative Screening Task Force, the American Cancer Society, the American College of Obstetricians and Gynecologists, and the American Geriatric Society.

scholarly journals The evolving landscape of sex-based differences in lung cancer: a distinct disease in women

2022 ◽  
Vol 31 (163) ◽  
pp. 210100
Author(s):  
Meera Ragavan ◽  
Manali I. Patel
Keyword(s):  
Lung Cancer ◽  
Lung Cancer Risk ◽  
Incidence Rates ◽  
Mortality Benefit ◽  
Ongoing Research ◽  
Screening Guidelines ◽  
The World ◽  
Distinct Disease ◽  
Changing Demographics ◽  
Current Screening

In stark contrast to a few decades ago when lung cancer was predominantly a disease of men who smoke, incidence rates of lung cancer in women are now comparable to or higher than those in men and are rising alarmingly in many parts of the world. Women face a unique set of risk factors for lung cancer compared to men. These include exogenous exposures including radon, prior radiation, and fumes from indoor cooking materials such as coal, in addition to endogenous exposures such as oestrogen and distinct genetic polymorphisms. Current screening guidelines only address tobacco use and likely underrepresent lung cancer risk in women. Women were also not well represented in some of the landmark prospective studies that led to the development of current screening guidelines. Women diagnosed with lung cancer have a clear mortality benefit compared to men even when other clinical and demographic characteristics are accounted for. However, there may be sex-based differences in outcomes and side effects of systemic therapy, particularly with chemotherapy and immunotherapy. Ongoing research is needed to better investigate these differences to address the rapidly changing demographics of lung cancer worldwide.

scholarly journals Eighteen Month Interval Growth of Terminal Ileal Primary Adenocarcinoma: A Consideration for Current Screening Guidelines

2017 ◽  
Vol 11 (3) ◽  
pp. 780-785
Author(s):  
Matthew Nazari ◽  
Alice Lee ◽  
Jared Rosenblum ◽  
Tilak Baba ◽  
Samuel Kallus
Keyword(s):  
Small Intestine ◽  
Terminal Ileum ◽  
Initial Evaluation ◽  
Primary Adenocarcinoma ◽  
Gastrointestinal Malignancies ◽  
Screening Guidelines ◽  
Current Screening

Primary adenocarcinoma of the small intestine comprises one of the rarest gastrointestinal malignancies. Further, the terminal ileum is very seldom implicated. This entity occurs sporadically and evades traditional colonoscopic evaluation in which the terminal ileum is not visualized. Herein, a case of interval development of primary terminal ileal adenocarcinoma over a 2-year period is reported as followed by direct endoscopic and colonoscopic visualization. This case demonstrates cecal involvement not found on initial evaluation without the provision of terminal ileum intubation. Relevant guidelines regarding the evaluation of the terminal ileum in routine colonoscopy are reviewed.

scholarly journals Month: Unilateral Peripheral Lung Opacity » Medical Image of the Month: Bleomycin-Induced Pulmonary Fibrosis in a Patient with Lymphoma

2021 ◽  
Vol 23 (2) ◽  
pp. 49-51
Author(s):  
Martin Dufwenberg ◽  
Keyword(s):  
Pulmonary Fibrosis ◽  
Medical Image ◽  
Chemotherapy Regimen ◽  
Signs And Symptoms ◽  
Close Monitoring ◽  
Screening Guidelines ◽  
Interstitial Pulmonary Fibrosis ◽  
Peripheral Lung ◽  
Function Testing ◽  
Current Screening

Interstitial pulmonary fibrosis is the most feared complication of bleomycin therapy and occurs in up to ten percent of patients that receive the drug. The risk of bleomycin-induced pulmonary fibrosis is related to the age of the patient, the dose of medication given, the patient’s kidney function, and whether the patient smokes cigarettes. Current screening guidelines for bleomycin-induced lung injury are limited, but most clinicians screen high risk and symptomatic patients with pulmonary function testing. This case report is of a patient with lymphoma who received bleomycin as a part of his chemotherapy regimen, and later developed pulmonary fibrosis complicated by bouts of eosinophilic multifocal pneumonia. The case highlights the importance of close monitoring of patients taking bleomycin for signs and symptoms of pulmonary fibrosis and the need for major medical societies to issue concrete screening guidelines.

Sign in / Sign up

Export Citation Format

Share Document